Black Patients with Metastatic Castrate-Resistant Prostate Cancer Have a Shorter Time Interval Between PSA and Clinical Progression on Novel Hormonal Therapies plus Avelumab
The Oncologist · 2023
DOI: 10.1093/oncolo/oyac203 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift The Oncologist, 2023. Verfasst von Charlotte Manogue Hawkins und 9 weiteren Autor:innen. Beteiligte Einrichtung: Tulane Office of Clinical Research, Tulane School of Medicine, New Orleans, LA, USA. Hauptthemen laut MEDLINE: Prostate-Specific Antigen, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: EMD Serono, Merck KGaA, Pfizer Pharmaceuticals.
Abstract (Originalsprache)
Background
Black men are at higher risk for prostate cancer death. Previous studies showed a benefit of different therapies, including immune-based therapy, for Black men with metastatic prostate cancer. We sought to explore the efficacy of the PD-L1 inhibitor avelumab in Black men with metastatic castrate-resistant prostate cancer (mCRPC) progressing after abiraterone or enzalutamide.
Methods
This pilot phase II study enrolled self-identified Black patients who developed mCRPC on next-generation hormonal therapies (NHTs) abiraterone acetate or enzalutamide (NCT03770455). Enrolled patients received avelumab 10mg/kg IV every 2 weeks while remaining on the same NHTs. The primary endpoint of our study was ≥ 50% reduction in prostate specific antigen (PSA) at ≥8 weeks.
Results
A total of eight patients were enrolled. The median duration on NHTs prior to enrollment was 364 days (95% CI, 260.9-467.1). The median time to initiate avelumab was 8 days (3-14). With a median follow-up of 196 days, no patients achieved the primary endpoint. The median time to PSA progression was 35 days (95 CI%, 0-94.8) and the median time to radiographic and/or clinical progression was 44 days (95 CI%, 0-118.5). The study was closed prematurely due to safety concerns related to the rapid clinical progression observed in the patients enrolled on study.
Conclusion
In conclusion, the addition of avelumab to NHT did not demonstrate clinical activity in Black men with new mCRPC. The unexpected short interval between PSA and radiographic and/or clinical progression observed in this study has potential clinical implications. ClinicalTrials.gov Identifier: NCT03770455 (IND number 139559).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Tulane Office of Clinical Research, Tulane School of Medicine, New Orleans, LA, USA.
- Tulane School of Medicine, New Orleans, LA, USA.
- University Hospitals Seidman Cancer Center, Cleveland, OH, USA.
ORCID-Profile: Pedro C Barata, Jodi Layton
Förderung
- EMD Serono
- Merck KGaA
- Pfizer Pharmaceuticals
Zitieren
APA
Hawkins, C. M., Barata, P. C., Cotogno, P., Davis, G., Jaeger, E., Ledet, E., Miller, P., Lewis, B., Sartor, O., & Layton, J. (2023). Black Patients with Metastatic Castrate-Resistant Prostate Cancer Have a Shorter Time Interval Between PSA and Clinical Progression on Novel Hormonal Therapies plus Avelumab. The Oncologist. https://doi.org/10.1093/oncolo/oyac203
Vancouver
Hawkins CM, Barata PC, Cotogno P, Davis G, Jaeger E, Ledet E, et al. Black Patients with Metastatic Castrate-Resistant Prostate Cancer Have a Shorter Time Interval Between PSA and Clinical Progression on Novel Hormonal Therapies plus Avelumab. The Oncologist. 2023. doi:10.1093/oncolo/oyac203
BibTeX
@article{Hawkins2023,
author = {Hawkins, Charlotte Manogue and Barata, Pedro C and Cotogno, Patrick and Davis, Gaynelle and Jaeger, Ellen and Ledet, Elisa and Miller, Patrick and Lewis, Brian and Sartor, Oliver and Layton, Jodi},
title = {Black Patients with Metastatic Castrate-Resistant Prostate Cancer Have a Shorter Time Interval Between PSA and Clinical Progression on Novel Hormonal Therapies plus Avelumab},
journal = {The Oncologist},
year = {2023},
doi = {10.1093/oncolo/oyac203}
}
EUVIMED